Findings

What do systematic reviews say?

7 questions · 7 findings · 3 reviews · Heart

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 14.3%Low 1 · 14.3%Moderate 3 · 42.9%High 2 · 28.6%

Angiotensin receptor blockers (ARBs) vs placebo or no treatment

All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction

Angiotensin receptor blockers (ARBs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (high certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 1.01 [0.92, 1.11]
4 studies · 7964 participants
High

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction

Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 1.04 [0.75, 1.45]
5 studies · 1187 participants
Moderate

Angiotensin receptor neprilysin inhibitors (ARNIs) vs usual care

All‐cause mortality (RR) Range of · patients with chronic heart failure with preserved ejection fraction

Angiotensin receptor neprilysin inhibitors (ARNIs) leads to lower all‐cause mortality (RR) Range of compared with usual care (high certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 0.97
3 studies · 7663 participants
High

Dopamine‐milrinone vs dopamine‐dobutamine

All‐cause short‐term mortality: at intensive care unit · adults with cardiogenic shock

It is very uncertain whether dopamine‐milrinone changes all‐cause short‐term mortality: at intensive care unit compared with dopamine‐dobutamine (very low certainty).

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
RR 1 [0.34, 2.93]
1 study · 20 participants
Very low

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

All‐cause mortality · patients with chronic heart failure with preserved ejection fraction

Mineralocorticoid receptor antagonists (MRAs) showed no clear difference in all‐cause mortality compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 0.91 [0.78, 1.06]
5 studies · 4207 participants
Moderate

Nurse‐led titration vs usual care

All‐cause mortality · people with heart failure with reduced ejection fraction

Nurse‐led titration probably leads to lower all‐cause mortality compared with usual care (moderate certainty).

1 finding from 1 review

Nurse‐led titration of angiotensin converting enzyme inhibitors, beta‐adrenergic blocking agents, and angiotensin… 2015 · Cochrane Headline outcomes only
RR 0.66 [0.48, 0.92]
6 studies · 902 participants
Moderate

Beta‐blockers vs placebo or no treatment

All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction

Beta‐blockers showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (low certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 0.82 [0.67, 1]
4 studies · 1105 participants
Low